Focused On-demand Library for Leptin receptor

Focused On-demand Libraries - Receptor.AI Collaboration


Explore the Potential with AI-Driven Innovation

This extensive focused library is tailor-made using the latest virtual screening and parameter assessment technology, operated by the Receptor.AI drug discovery platform. This technique is more effective than traditional methods, offering compounds with improved activity, selectivity, and safety.


From a virtual chemical space containing more than 60 billion molecules, we precisely choose certain compounds. Reaxense aids in their synthesis and provision.


The library features a range of promising modulators, each detailed with 38 ADME-Tox and 32 physicochemical and drug-likeness parameters. Plus, each compound is presented with its ideal docking poses, affinity scores, and activity scores, ensuring a thorough insight.


We utilise our cutting-edge, exclusive workflow to develop focused libraries for receptors.


 

Fig. 1. The screening workflow of Receptor.AI

This includes comprehensive molecular simulations of the receptor in its native membrane environment, paired with ensemble virtual screening that factors in its conformational mobility. In cases involving dimeric or oligomeric receptors, the entire functional complex is modelled, pinpointing potential binding pockets on and between the subunits to capture the full range of mechanisms of action.


Key features that set our library apart include:


  • The Receptor.AI platform integrates extensive information about the target protein, such as historical experiments, academic research, known ligands, and structural insights, thereby increasing the likelihood of identifying highly relevant compounds.

  • The platform’s sophisticated molecular simulations are designed to discover potential binding sites, ensuring that our focused library is optimal for the discovery of allosteric inhibitors and binders for cryptic pockets.

  • With over 50 customisable AI models, verified through extensive testing in commercial drug discovery and research, Receptor.AI is efficient, reliable, and precise. These models are essential in the production of our focused libraries.

  • Receptor.AI not only produces focused libraries but also provides full services and solutions at every stage of preclinical drug discovery, with a success-based pricing structure that aligns our interests with the success of your project.

PARTNER
Receptor.AI
 
UPACC
P48357

UPID:
LEPR_HUMAN

ALTERNATIVE NAMES:
HuB219; OB receptor

ALTERNATIVE UPACC:
P48357; Q13592; Q13593; Q13594; Q92919; Q92920; Q92921

BACKGROUND:
The Leptin receptor, encoded by the gene with accession number P48357, serves as a critical mediator of leptin's central and peripheral effects. It influences food intake, energy expenditure, insulin secretion, and immune function by activating signaling pathways such as STAT3 and MAPK. Additionally, it plays a role in transporting leptin across the blood-brain barrier and mediates leptin endocytosis, highlighting its importance in maintaining energy balance and metabolic homeostasis.

THERAPEUTIC SIGNIFICANCE:
Given its involvement in leptin receptor deficiency, which leads to early-onset severe obesity and immune function alterations, the leptin receptor emerges as a key target in developing therapeutic strategies for obesity and related metabolic diseases. Exploring its function further could unlock new avenues for treatment.

Looking for more information on this library or underlying technology? Fill out the form below and we will be in touch with all the details you need.


Page 81 of 8789